INACTIVE

AstraZeneca PLC ADRhedged

AZNH
ETF Ticker

-1.75%

+18.04%

Cboe BZX

Equity

United Kingdom

Single Asset

The AstraZeneca PLC ADRhedged, AZNH_US, is listed on the Cboe BZX. The fund provides exposure to United Kingdom, Single Asset Equity and has assets under management of $1.6m (as of Jan 30, 2026). The ETF trades in USD and was listed on the exchange on Oct 1, 2024. It has a net expense ratio of 19bps. (All data in USD as of Jan 30, 2026 unless stated.)

The underlying strategy provides no continuing investment exposure because the fund has been liquidated following termination of AstraZeneca’s ADR program. The fund never tracked a specified index; before liquidation, it sought to correspond, before fees and expenses, to the total return of AstraZeneca ordinary shares in their local market while reducing USD-versus-GBP fluctuations. Under normal circumstances, at least 95% of net assets was invested in AstraZeneca ADRs, without direct ownership of ordinary shares. A currency swap exchanged USD exposure for GBP, with notional adjusted daily to the current value of the ADR position; the swap was marked to market and settled daily. Residual assets could be held in cash or cash equivalents. After the ADR program ended, the ADRs were mandatorily converted into ordinary shares, those shares were sold, and proceeds were distributed. There is therefore no current composition, weighting, reconstitution, or rebalancing process.

ETF Details

Key Facts

Issuer:
ADRhedged
AUM:
$1.6m (as of Jan 30, 2026)
Net Expense Ratio:
19 bps
Inception Date:
Oct 1, 2024
Index:
N/A
Dividend Frequency:
N/A

Trading

Ticker:
AZNH
Exchange:
Cboe BZX
ISIN:
US74016W3043
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United Kingdom
Theme:
Single Asset
Economic Development:
Developed Markets
1 Year Volatility:
24.98%
3 Year Volatility:
N/A
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
1.26% (verify with issuer)
1 Month Performance:
-2.45%
3 Month Performance:
6.61%
6 Month Performance:
16.08%
1 Year Performance:
18.04%
3 Year Performance:
N/A
5 Year Performance:
N/A
Investment Proposition

AstraZeneca PLC ADRhedged (AZNH) offers targeted exposure to AstraZeneca’s equity performance while embedding a systematic currency hedge designed to reduce the impact of GBP–USD fluctuations on U.S.-based investors. The strategy seeks to align U.S. investor outcomes with the company’s local-market return stream by pairing ADR exposure with a rules-based overlay that offsets day-to-day exchange-rate noise. This creates a single-name, currency-aware sleeve where stock-specific factors—pipeline execution, regulatory milestones, competitive dynamics, and capital allocation—drive results more than macro FX swings. Return and risk characteristics reflect large-cap biopharma: defensible cash flows from diversified therapeutics, potential step-changes around clinical/readout cycles, and sensitivity to policy and patent cliffs. In portfolios, AZNH can serve as a thematic satellite for healthcare conviction, a currency-neutral expression of a single-issuer view, or a tactical overlay to neutralize sterling risk without dismantling equity exposure. Appropriate users include research-driven advisors expressing high-conviction single-stock ideas and institutions separating security selection from currency management. A fund-specific consideration is single-issuer concentration combined with hedge implementation and counterparty dynamics, which warrants ongoing oversight.

ETF Analytics

Fund Discovery

4 Suggestions